Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Denison Mines Corp Ordinary Shares (Canada) (DNN) vs Novartis AG (NVS) Price & Performance

Denison Mines Corp Ordinary Shares (Canada)Trade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Denison Mines Corp Ordinary Shares (Canada) vs Novartis AG — how do they compare? Denison Mines Corp Ordinary Shares (Canada) trades at $2.38 (market cap $2.33B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 117.6× Denison Mines Corp Ordinary Shares (Canada)'s market cap, and Novartis AG pays a 3.31% dividend while Denison Mines Corp Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Denison Mines Corp Ordinary Shares (Canada) for 0 Days and Novartis AG for 82 Days on average.

DNNNVS
Market Cap
$2.33B$274.00B
Volume
20,155,8491,852,137
Sector
EnergyHealth
52-Week High
$4.37$168.62
52-Week Low
$2.27$121.80
Typical Hold Time
0 Days82 Days
Enterprise Value
$2.17B$315.32B
Dividend Yield
—3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Denison Mines Corp Ordinary Shares (Canada)

No Aura AI signal available yet.

Novartis AG

Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.

Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNN
100% Buy0% Sell
Avg holding period · 0 Days
NVS
100% Buy0% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About Denison Mines Corp Ordinary Shares (Canada)

Denison Mines is a uranium mining, development, and exploration company focused on Canada's Athabasca Basin. Its portfolio includes the Wheeler River project and interests in other uranium projects and processing facilities.

Read more on DNN →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →